MX2018012655A - Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. - Google Patents
Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.Info
- Publication number
- MX2018012655A MX2018012655A MX2018012655A MX2018012655A MX2018012655A MX 2018012655 A MX2018012655 A MX 2018012655A MX 2018012655 A MX2018012655 A MX 2018012655A MX 2018012655 A MX2018012655 A MX 2018012655A MX 2018012655 A MX2018012655 A MX 2018012655A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods
- treating neurological
- cardiovascular conditions
- conditions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a compuestos y métodos de uso de los mismos para el tratamiento de ciertos trastornos y afecciones, por ejemplo, lesiones cerebrales tales como accidente cerebrovascular o lesiones cerebrales traumáticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662325860P | 2016-04-21 | 2016-04-21 | |
PCT/US2017/028996 WO2017185061A1 (en) | 2016-04-21 | 2017-04-21 | Compounds and methods for treating neurological and cardiovascular conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018012655A true MX2018012655A (es) | 2019-09-06 |
Family
ID=60022855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012655A MX2018012655A (es) | 2016-04-21 | 2017-04-21 | Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. |
Country Status (12)
Country | Link |
---|---|
US (6) | US9789131B1 (es) |
EP (1) | EP3445368A4 (es) |
JP (2) | JP7109005B2 (es) |
KR (2) | KR102445887B1 (es) |
CN (2) | CN114903903A (es) |
AU (2) | AU2017254720B2 (es) |
BR (1) | BR112018071560A2 (es) |
CA (1) | CA3020490A1 (es) |
EA (1) | EA201892008A1 (es) |
IL (2) | IL262487B (es) |
MX (1) | MX2018012655A (es) |
WO (1) | WO2017185061A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA120628C2 (uk) | 2014-11-07 | 2020-01-10 | Басф Се | Пестицидні суміші |
WO2017157916A1 (en) | 2016-03-16 | 2017-09-21 | Basf Se | Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean |
BR112018068695B1 (pt) | 2016-03-16 | 2022-12-27 | Basf Se | Uso de um composto e método para controlar fungos fitopatogênicos |
CA3015744C (en) | 2016-03-16 | 2024-04-23 | Basf Se | Use of 1-[2-[[1-(4-chlorophenyl)pyrazol-3-yl]oxymethyl]-3-methyl-phenyl]-4-methyl-tetrazol-5-one for combating resistant phytopathogenic fungi on cereals |
KR102445887B1 (ko) | 2016-04-21 | 2022-09-21 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법 |
WO2019157317A1 (en) * | 2018-02-09 | 2019-08-15 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating addiction and related disorders |
EP3801537A4 (en) * | 2018-05-26 | 2022-08-03 | Primetime Life Sciences, LLC | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN COUPLED RECEPTORS |
WO2020061211A1 (en) * | 2018-09-18 | 2020-03-26 | Saint Louis University | Use of highly-selective adenosine 3a receptor subtype agonists |
US10765693B2 (en) * | 2018-09-26 | 2020-09-08 | Astrocyte Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
JP7282324B2 (ja) * | 2018-12-11 | 2023-05-29 | 株式会社島津製作所 | イオン化装置、質量分析装置および流体試料の分析方法 |
US20220218712A1 (en) * | 2019-02-25 | 2022-07-14 | Saint Louis University | Treatment of alzheimer's disease |
EP4329773A1 (en) * | 2021-04-28 | 2024-03-06 | Astrocyte Pharmaceuticals, Inc. | Purine nucleosides, their intermediates, and methods of preparation thereof |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69428536T2 (de) | 1993-07-13 | 2002-06-06 | Nasa | A3 -adenosin -rezeptor agonisten |
US7348315B2 (en) | 1995-03-23 | 2008-03-25 | The University Of Connecticut | Methods of treating heart failure with modified ATP, ADP and AMP compounds |
IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
US6586413B2 (en) | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
WO2001051490A1 (en) | 2000-01-14 | 2001-07-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methanocarba cycloalkyl nucleoside analogues |
US7589075B2 (en) | 2001-01-16 | 2009-09-15 | Can-Fite Biopharma Ltd. | Use of an adenosine A3 receptor agonist for inhibition of viral replication |
US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
CA2507044A1 (en) | 2002-11-21 | 2004-06-10 | Mary Lucero | Purinergic modulation of smell |
ES2287804T3 (es) * | 2003-12-29 | 2007-12-16 | Can-Fite Biopharma Ltd. | Metodo para el tratamiento de esclerosis multiples. |
GB0405009D0 (en) * | 2004-03-05 | 2004-04-07 | Cambridge Biotechnology Ltd | Analgesics |
US7825126B2 (en) | 2004-09-09 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Purine derivatives as A3 and A1 adenosine receptor agonists |
WO2006091905A1 (en) * | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
WO2007020018A1 (en) | 2005-08-12 | 2007-02-22 | Universite Libre De Bruxelles | Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies |
DK2049127T3 (en) | 2006-05-23 | 2015-01-05 | Univ Connecticut | N-METHANOCARBA DERIVATIVES FOR TREATMENT OF HEART DISEASES |
WO2008021552A2 (en) | 2006-08-18 | 2008-02-21 | Duke University | Biased ligands and methods of identifying same |
US7867983B2 (en) | 2007-03-29 | 2011-01-11 | The University Of Connecticut | Methods to protect skeletal muscle against injury |
US20090088403A1 (en) | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
WO2009010871A2 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Pyrazole derivatives as antagonists of adenosine a3 receptor |
ES2490606T3 (es) | 2007-10-15 | 2014-09-04 | Can-Fite Biopharma Ltd. | Procedimiento para inducir proliferación de hepatocitos y usos del mismo |
CN101925610A (zh) | 2007-11-23 | 2010-12-22 | 巴尔-伊兰大学 | 不可水解的二磷酸核苷或三磷酸核苷衍生物及其用途 |
AU2009231978C1 (en) * | 2008-03-31 | 2014-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as A3 adenosine receptor- selective agonists |
US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
CN104491864A (zh) | 2008-04-21 | 2015-04-08 | 奥德纳米有限公司 | 用于治疗耳部疾病和病况的耳用调配物及方法 |
US8399018B2 (en) | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
US8796291B2 (en) | 2008-08-01 | 2014-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
WO2010121023A2 (en) | 2009-04-15 | 2010-10-21 | The Regents Of The University Of California | Peptides and aptamers for targeting of neuron or nerves |
WO2011068978A1 (en) | 2009-12-02 | 2011-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methanocarba adenosine derivatives and dendrimer conjugates thereof |
WO2011077435A1 (en) | 2009-12-22 | 2011-06-30 | Bar-Ilan University | Compositions and methods for reducing intraocular pressure |
PL2539352T3 (pl) | 2010-02-22 | 2018-03-30 | University Of Connecticut | Pochodne amp do leczenia chorób serca |
US8691775B2 (en) | 2010-04-19 | 2014-04-08 | Back Bay Scientific, Llc | Use of drugs that activate P2Y receptors to enhance synaptogenesis |
US9132131B2 (en) | 2011-04-21 | 2015-09-15 | Saint Louis University | Use of adenosine A3 receptor agonists for treatment of neuropathic pain |
WO2013049725A2 (en) | 2011-09-30 | 2013-04-04 | Tufts University | Methods of using adenosine a1 receptor activation for treating depression |
WO2014160502A1 (en) | 2013-03-13 | 2014-10-02 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
EP3074398B1 (en) | 2013-11-27 | 2021-03-17 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | A3 adenosine receptor agonists |
US20160024135A1 (en) | 2014-07-27 | 2016-01-28 | Zhejiang Subtropical Crops Research Institute | Adenosine receptor activation reagent and the uses of thereof |
CN107847503A (zh) | 2015-02-04 | 2018-03-27 | 贝克心脏与糖尿病研究所 | 一种治疗方法和用于所述治疗方法中的化合物 |
CN108685935B (zh) * | 2015-05-06 | 2019-10-11 | 浙江省亚热带作物研究所 | 一种含有腺苷受体激动试剂的食品 |
KR102445887B1 (ko) | 2016-04-21 | 2022-09-21 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법 |
CN109666053A (zh) * | 2017-10-16 | 2019-04-23 | 张家口华健致远生物科技有限公司 | 一种a3腺苷受体激动剂及其用途 |
WO2019157317A1 (en) | 2018-02-09 | 2019-08-15 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating addiction and related disorders |
US10765693B2 (en) | 2018-09-26 | 2020-09-08 | Astrocyte Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
-
2017
- 2017-04-21 KR KR1020187033797A patent/KR102445887B1/ko active IP Right Grant
- 2017-04-21 AU AU2017254720A patent/AU2017254720B2/en active Active
- 2017-04-21 CA CA3020490A patent/CA3020490A1/en active Pending
- 2017-04-21 CN CN202210281874.3A patent/CN114903903A/zh active Pending
- 2017-04-21 BR BR112018071560-3A patent/BR112018071560A2/pt active Search and Examination
- 2017-04-21 EP EP17786774.4A patent/EP3445368A4/en active Pending
- 2017-04-21 CN CN201780024816.XA patent/CN109310695B/zh active Active
- 2017-04-21 MX MX2018012655A patent/MX2018012655A/es unknown
- 2017-04-21 US US15/494,407 patent/US9789131B1/en active Active
- 2017-04-21 KR KR1020227032219A patent/KR20220132042A/ko not_active Application Discontinuation
- 2017-04-21 EA EA201892008A patent/EA201892008A1/ru unknown
- 2017-04-21 WO PCT/US2017/028996 patent/WO2017185061A1/en active Application Filing
- 2017-04-21 US US16/095,282 patent/US20220305044A1/en active Pending
- 2017-04-21 JP JP2018555672A patent/JP7109005B2/ja active Active
- 2017-08-07 US US15/670,738 patent/US10265338B2/en active Active
-
2018
- 2018-10-21 IL IL262487A patent/IL262487B/en unknown
-
2019
- 2019-03-14 US US16/353,737 patent/US10953031B2/en active Active
-
2021
- 2021-02-19 US US17/180,469 patent/US11484545B2/en active Active
- 2021-12-27 IL IL289423A patent/IL289423A/en unknown
-
2022
- 2022-04-06 JP JP2022063285A patent/JP2022088642A/ja active Pending
- 2022-09-21 US US17/934,169 patent/US20230165887A1/en active Pending
-
2023
- 2023-05-02 AU AU2023202694A patent/AU2023202694A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20190006501A (ko) | 2019-01-18 |
US20220305044A1 (en) | 2022-09-29 |
JP7109005B2 (ja) | 2022-07-29 |
US20180021363A1 (en) | 2018-01-25 |
US10953031B2 (en) | 2021-03-23 |
EP3445368A4 (en) | 2019-12-18 |
KR102445887B1 (ko) | 2022-09-21 |
KR20220132042A (ko) | 2022-09-29 |
IL262487A (en) | 2018-12-31 |
US9789131B1 (en) | 2017-10-17 |
US20220000899A1 (en) | 2022-01-06 |
EA201892008A1 (ru) | 2019-06-28 |
AU2017254720B2 (en) | 2023-02-02 |
AU2023202694A1 (en) | 2023-05-18 |
US20200046751A1 (en) | 2020-02-13 |
IL262487B (en) | 2022-02-01 |
JP2022088642A (ja) | 2022-06-14 |
CN114903903A (zh) | 2022-08-16 |
CA3020490A1 (en) | 2017-10-26 |
BR112018071560A2 (pt) | 2019-02-12 |
EP3445368A1 (en) | 2019-02-27 |
CN109310695A (zh) | 2019-02-05 |
CN109310695B (zh) | 2022-04-01 |
WO2017185061A1 (en) | 2017-10-26 |
US20230165887A1 (en) | 2023-06-01 |
US10265338B2 (en) | 2019-04-23 |
IL289423A (en) | 2022-02-01 |
AU2017254720A1 (en) | 2018-11-01 |
JP2019515920A (ja) | 2019-06-13 |
US11484545B2 (en) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018012655A (es) | Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. | |
HK1254665A1 (zh) | 預防、改善或治療退行性腦病或認知功能障礙的新型乳酸菌和組合物 | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
PH12019500751A1 (en) | Carbamoyl phenylalaninol compounds and uses thereof | |
MX2020006385A (es) | Composiciones y metodos para el tratamiento de trastornos neurologicos que comprenden una demencia. | |
PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
MX2021003515A (es) | Compuestos polimorficos y usos de los mismos. | |
MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
MX2020002762A (es) | Composiciones y métodos para tratar una lesión cerebral. | |
MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
ZA202002993B (en) | Compounds for the treatment of neuromuscular disorders | |
PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
PH12016501393B1 (en) | Substituted bicyclic heteroaryl compounds as rxr agonists | |
MX2020008138A (es) | Formulaciones parentales y usos de estas. | |
MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
PH12017501872A1 (en) | Methods of treating diseases | |
MX2016016118A (es) | Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo. | |
HK1257911A1 (zh) | 7,8二羥基黃酮在治療或預防老齡化相關的認知能力下降中的用途 | |
PH12017500500A1 (en) | C-20 steroid compounds, compositions and uses thereof to treat traumatic brain injury (tbi), including concussions |